Page 8 - Dr Reddy’s Laboratories
Dr Reddy's Labs shines among pharma stocks, wins investor confidence
The Hyderabad-based company is an outlier among large pharmaceutical producers, having seen a jump in its stock price over the previous year
 "Dr Reddy's Labs shines among pharma stocks, wins investor confidence")
Dr Reddy's to Lupin, Indian pharma players get a leg up from domestic sales
Dr Reddy's, Lupin, Sun Pharma and Cadila Healthcare outperformed the local industry growth in recent months, a trend expected to continue
 "Dr Reddy's to Lupin, Indian pharma players get a leg up from domestic sales")
Dr Reddy's Labs slumps 8% as US FDA issues CRL for its version of NuvaRing
A CRL is issued when the FDA decides not to approve new or generic drug application for marketing in its present form
 "Dr Reddy's Labs slumps 8% as US FDA issues CRL for its version of NuvaRing")
PSAI segment decline pulls down Dr Reddy's Q1 show
Earnings were driven by one-off gains
 "PSAI segment decline pulls down Dr Reddy's Q1 show")
Dr Reddy's Q1 net profit up 45% at Rs 663 cr on rise in generics business
A combination of factors, including an 8% growth in global generics business and the other operating income drove the growth in net profit of Dr Reddy's during the first quarter ended June, 2019
Dr Reddy's Laboratories unveils generic version of Allegra-D in US
Allegra-D 12 HR is a trademark of Aventisub II Inc
 "Dr Reddy's Laboratories unveils generic version of Allegra-D in US")
Dr Reddy's Q4 net up 44% to Rs 434 cr, annual profit doubles to Rs 1,879 cr
Divestment of derma assets, lower operating costs helped firm post higher profit growth during the quarter
 "Dr Reddy's Q4 net up 44% to Rs 434 cr, annual profit doubles to Rs 1,879 cr")
Dr Reddy's Laboratories renews focus on chronic segment; gets India head
The pharma major is on a restructuring drive
Dr Reddy's gets Chinese regulator nod for anti-blood clotting drug
Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems
 "Dr Reddy's gets Chinese regulator nod for anti-blood clotting drug")
USFDA completes Shreveport plant audit with zero observations: Dr Reddy's
Shares of Dr Reddy's Laboratories were trading at Rs 2,640 per scrip on BSE, up 2.11 per cent from their previous close
Dr Reddy's recalls 2,770 bags of epilepsy drug in US over labelling error
Such recalls are for dangerous or defective products that predictably can cause serious health problems
USFDA lifts warning letter on Dr Reddy's Duvvada plant in Andhra Pradesh
This is the second plant to come out of the warning letter after multiple inspections conducted by the US drug regulator
Dr Reddy's receives inspection closure report for its Duvvada facility
The site was again audited in October 2018, Dr Reddy's said.
Dr Reddy's Laboratories: Sustaining US gains critical for a rerating
Gains hinge on key launches; US FDA issues in some plants another hurdle
Dr Reddy's Laboratories: The wait for launching a key drug just got longer
Litigation issues, more competition could mean diminishing returns
Opioid treatment drug ban buzz drags Dr Reddy's 6% in a firm market
The stock dipped 6% to Rs 2,536 on the BSE in intra-day trade on back of heavy volumes.
Dr Reddy's Labs surges 8% on approval for generic Suboxone Film launch
The stock surged 8% to Rs 2,652 on the BSE in early morning trade, quoting near to its 52-week high of Rs 2,687 touched on September 28, 2018 in intra-day deal.
 "Dr Reddy's Labs surges 8% on approval for generic Suboxone Film launch")
Dr Reddy's Labs gains 3% on successful USFDA audit of Srikakulum plant
The stock of the pharmaceutical company was up 3% at Rs 2,546, trading higher for the sixth straight day, gaining 6% from Rs 2,407 on November 9, as compared to 1% rise in the S&P BSE Sensex.
Dr Reddy's slips 7% following 8 USFDA observations for Duvvada plant
The stock slipped 7% to Rs 2,425 on the BSE after the pharmaceutical company said US health regulator issued eight observations after inspecting its formulations plant at Duvvada, Visakhapatnam.
 "Dr Reddy's slips 7% following 8 USFDA observations for Duvvada plant")
Dr Reddy's gains 6% post September quarter results
The stock gained 6.5% to Rs 2,559 after the company reported a good operational performance in September quarter, on account of lower R&D, higher other income, financial income, and lower tax.
